Rocket Pharmaceuticals (RCKT) awards 150,000 RSUs to director for consulting
Rhea-AI Filing Summary
Rocket Pharmaceuticals reported that director David P. Southwell received 150,000 restricted stock units on August 3, 2026 as compensation under a July 21, 2026 consulting agreement covering strategic and financial activities. The RSUs convert one-for-one into common stock and vest beginning August 3, 2027, with the balance vesting in equal quarterly installments over the following two years. After this award, Southwell holds 204,522 shares directly and 113,124 shares indirectly through The David P. Southwell Irrevocable Trust dated April 14, 2024.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 150,000 shares
Net Buy
2 txns
Insider
SOUTHWELL DAVID P
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Common Stock F1, F2 | 150,000 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 204,522 shares (Direct);
Common Stock — 113,124 shares (Indirect, By The David P. Southwell Irrevocable Trust Dtd 04/14/2024)
Footnotes (2)
- F1. Rocket Pharmaceuticals, Inc. (the "Company") entered into a consulting agreement with the Reporting Person, dated July 21, 2026, for consulting services related to the Company's strategic and financial activities. As compensation for services rendered, the Reporting Person received 150,000 restricted stock units ("RSUs") on August 3, 2026.
- F2. Represents RSUs that convert to common stock on a one-for-one basis. One-third of such RSUs will vest in full on August 3, 2027, with the remaining two-thirds vesting in equal quarterly installments over the following two years.
Key Figures
RSUs granted: 150,000 units
Direct holdings after grant: 204,522 shares
Indirect holdings via trust: 113,124 shares
3 metrics
RSUs granted
150,000 units
Restricted stock units received August 3, 2026 as consulting compensation
Direct holdings after grant
204,522 shares
Common stock held directly by David P. Southwell after the reported RSU award
Indirect holdings via trust
113,124 shares
Common stock held indirectly through The David P. Southwell Irrevocable Trust Dtd 04/14/2024
Key Terms
restricted stock units, consulting agreement, irrevocable trust, vest
4 terms
restricted stock units financial
"received 150,000 restricted stock units ("RSUs") on August 3, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
consulting agreement financial
"entered into a consulting agreement with the Reporting Person, dated July 21, 2026"
irrevocable trust financial
"By The David P. Southwell Irrevocable Trust Dtd 04/14/2024"
An irrevocable trust is a legal arrangement where an owner transfers assets into a separate entity managed by a trustee and gives up the power to modify or reclaim those assets. For investors it matters because putting stock or other holdings into such a trust can change who controls and benefits from the assets, affect taxes and creditor protection, and influence how easy it is to sell or value those holdings—like placing valuables in a locked safe overseen by someone else.
vest financial
"One-third of such RSUs will vest in full on August 3, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider equity award did Rocket Pharmaceuticals (RCKT) report for David P. Southwell?
Rocket Pharmaceuticals reported that director David P. Southwell received 150,000 restricted stock units (RSUs) on August 3, 2026. The award was granted as compensation for consulting services related to the company’s strategic and financial activities under a consulting agreement dated July 21, 2026.
What are the vesting terms of the 150,000 RSUs granted by Rocket Pharmaceuticals (RCKT) to David P. Southwell?
The 150,000 RSUs convert to common stock on a one-for-one basis. One-third vests on August 3, 2027, and the remaining two-thirds vest in equal quarterly installments over the following two years, creating a multi-year vesting schedule tied to ongoing service.
Why did Rocket Pharmaceuticals (RCKT) grant RSUs to director David P. Southwell?
Rocket Pharmaceuticals granted the RSUs as compensation for consulting services. A consulting agreement dated July 21, 2026 covers Southwell’s work on the company’s strategic and financial activities, with the August 3, 2026 RSU award serving as consideration for those services.
Was the Rocket Pharmaceuticals (RCKT) Form 4 transaction for David P. Southwell made under a Rule 10b5-1 trading plan?
The Form 4 indicates the transaction was not conducted under a Rule 10b5-1 trading plan. The document-level Rule 10b5-1 checkbox is marked as false, and no footnote states that the award was granted pursuant to such a plan.